access to care 279–80, 299–300
ADAPT see Adolescent Depression,
Antidepressants and Psychotherapy Trial
ADHD see attention deficit hyperactivity
disorder
adjustment disorder
with depressed mood 4
diagnosis 4–5
old age depression 202, 205
primary care 326
psychotherapies 98–9
adolescent depression
bipolar disorder 163, 165–6, 184, 194
cob-morbidity 154–5, 193
diagnosis 153–4, 165–6, 192–3
epidemiology 145
pharmacological treatment 160–1, 194
psychotherapies 157, 159–60, 189–90, 194
puberty 148–9
see also childhood depression
Adolescent Depression, Antidepressants and
Psychotherapy Trial (ADAPT) 156–7, 165
aetiology
childhood depression 149–51, 181
diagnosis 1, 6, 20, 38
old age depression 208–9
primary care 275–6
affective disorders 36
Agence Francaise de Securite Sanitaire des
Produits de Sante (AFSSAPS) 92, 164
Agency for Health Care Policy Research
(AHCPR) 290
agomelatine 51–2
AHCPR see Agency for Health Care Policy
Research
alcoholism 155
allegiance effect 105, 120
Alma Ata Declaration 271–2
alpha-2 adrenergic receptor antagonists 57–8
Alzheimer’s disease 199, 201, 204–5, 208, 262
American Psychiatric Association (APA) see
Diagnostic and Statistical Manual of
Mental Disorders
amitriptyline 54, 96, 121
amoxapine 53
ante-partum depressive disorders 99–100
antipsychotics 82
anxiety
childhood depression 193
dementia caregivers 262–3
diagnosis 2, 18, 21, 32
old age depression 209, 262–3
primary care 320, 323
psychotherapies 98–9, 104
APA see Diagnostic and Statistical Manual of
Mental Disorders
attention deficit hyperactivity disorder (ADHD)
148, 154, 163
atypical features 11–12
Australian Mental Health and Wellbeing study
202–3
Axis II cluster C personality disorders 104
Bayesian graphs 284–5
BDI see Beck Depression Inventory
BDP see brief dynamic psychotherapy
Beck Depression Inventory (BDI) 153
behaviour therapy (BT) 95, 117–19
benzodiazepines 229
bereavement 2, 32, 326
bipolar disorder
childhood depression 163, 165–6, 183–4, 194
diagnosis 4
old age depression 260
primary care 320
Black Dog Institute 41–2
blind outcome assessment 227
breastfeeding 99
Brief COPE 262
brief dynamic psychotherapy (BDP) 95, 120–2

Depressive Disorders  Third Edition  Edited by Helen Herrman, Mario Maj and Norman Sartorius
© 2009 John Wiley & Sons, Ltd
broparomine 59
BT see behaviour therapy
bupropion 50, 53, 58–9, 90

Canadian Task Force on Preventative Health Care (CTFPHC) 285, 287
CAPA see Child and Adolescent Psychiatric Assessment
Cardiac Randomised Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) 102
CAS see Child Assessment Schedule
caseness 2, 5, 31–4, 46
CBASP see Cognitive Behavioural Analysis System of Psychotherapy
CBT see cognitive behaviour therapy
CDI see Children’s Depression Inventory
CDRS-R see Children’s Depression Rating Scale-Revised
CGAS see Children’s Global Assessment Scale
Child and Adolescent Psychiatric Assessment (CAPA) 154
Child Assessment Schedule (CAS) 154
childhood depression 145–94
aetiology 149–51, 181
bipolar disorder 163, 165–6, 183–4, 194
classification 146–7
co-morbidity 154–5, 157–8, 193
developing countries 180–1
developmental considerations 147–9
diagnosis 146–7, 152–3, 165–6, 180–1, 192–3
epidemiology 145–6, 162
evidence 167–8
genetic/environmental factors 149–50, 190, 193
infantile depression 147–8
management 156–65
pharmaceutical treatment 160–5, 168, 186–7
practice parameters 163–4
psychotherapies 156–60, 162, 167, 186, 189–90, 194
relapse/recurrence 155, 180
research developments 168–9
resistance to treatment 162–3
suicidality 155–6, 161–2, 165, 180, 194
see also adolescent depression
Children’s Depression Inventory (CDI) 153
Children’s Depression Rating Scale-Revised (CDRS-R) 153, 156
Children’s Global Assessment Scale (CGAS) 157, 160
CHMP see Committee on Human Medicinal Products
chronic depression 102, 232–3, 277
citalopram
childhood depression 164
major depression 89
old age depression 212, 214, 217
psychotherapies 100, 110
clinical effectiveness 291–4
cluster analysis 15, 18
Cochrane Collaboration 211–12, 216, 286
cognitive behaviour therapy (CBT) 95, 104–17
acute phase efficacy 105–11, 119
childhood depression 156–7, 159, 164, 167, 186–7
continuation phase 113–14
delivery models 111–13
developing countries 141
evidence 133
neurological correlates 116–17
old age depression 217–19, 263
primary care 276, 326
relapse/recurrence 113–15
Cognitive Behavioural Analysis System of Psychotherapy (CBASP) 105, 108–9
cognitive impairment 199–201
CoI see cost of illness
collaborative care 285–6, 288–9, 291–8, 301–2, 305, 308
Collaborative Depression Study 40
Committee on Human Medicinal Products (CHMP) 161
Committee on Safety of Medicines (CSM) 161
community studies 231–3
compliance 293–5
computed tomography (CT) 198
computer-assisted CBT 112
consultation–liaison 288, 291, 301
Continuous Morbidity Registry 277
continuous quality improvement (CQI) 290
CORE scores 16, 19
cost of illness (CoI) studies 278
cost-effectiveness 296–9, 306–7
CQI see continuous quality improvement
CREATE see Cardiac Randomised Evaluation of Antidepressant and Psychotherapy Efficacy
criteria-based diagnosis 35–6
CSM see Committee on Safety of Medicines
CT see computed tomography
CTFPHC see Canadian Task Force on Preventative Health Care
cultural factors 140–1, 265–6
cyclothymia 4
Danish University Antidepressant Group (DUAG) 19, 38
DDIs see drug–drug interactions
deep white matter lesions (DWMLs) 230
dementia
  caregivers 262–3
diagnosis 21, 199–200
electroconvulsive therapy 223–4
epidemiology 203–5
pharmacological treatment 216, 269
psychotherapies 219, 223–4, 263
depressed affects 2
depressed moods 2, 4
desipramine 106
dexamethasone suppression test (DST) 41
dextrimethorphan 60
Diagnostic Interview Schedule for Children and Adolescents (DICA) 154
Diagnostic and Statistical Manual of Mental Disorders (DSM) 1
alternative models 27–9
caseness 2, 5, 31–3
categorical specifiers 10–12
childhood depression 146–7, 152
concerns 5–7, 14
dimensional models 37–8
functionalised diagnosis 45
old age depression 198–9, 202–5, 228, 231, 258–9
overview 3–4
primary care 275, 277, 281, 322
psychotherapies 107, 140
research and treatment difficulties 9–12
diagnosis 1–46
alternative models 27–9, 35–6
binary versus unitary models 7–8, 13–14
caseness 2, 5, 31–4, 46
childhood depression 146–7, 152–4, 165–6, 180–1, 192
classificatory systems 1, 2–7, 27–9, 35–6
criteria-based diagnosis 35–6
definitions 2
depression rating scales 281–4
dimensional models 9, 29, 37–9
evidence 22
functionalised diagnosis 44–6
future developments 22–3
historical overview 7–8
interviews 153–4
mixed subtyping model 1, 15–22
nonmelancholic depression 15–22, 27, 32–3, 41
old age depression 198–201, 228, 231, 258, 265–6
overdiagnosis 5–7
overview 3–5
personality structure 46
pharmacological treatment 82, 86
primary care 275, 277, 280–7, 322–3, 328–9
psychotherapies 107, 140, 143–4
questionnaires 149, 153
research and treatment difficulties 9–13
statistical analysis 7–8, 16
subtyping models 8–9, 14–22
treatment implications 6–7
DICA see Diagnostic Interview Schedule for Children and Adolescents
discontinuation syndromes 56
dietary amines 60
differential diagnosis 193
diffused tensor imaging (DTI) 208
dimensional models 9, 29, 37–9
disability 206–7
dose–response curves 48–9, 84
dothiepin 214
double depression 4, 36, 155
drug–drug interactions (DDIs) 269
DSM see Diagnostic and Statistical Manual of Mental Disorders
DST see dexamethasone suppression test
DTI see diffused tensor imaging
DUAG see Danish University Antidepressant Group
duloxetine 56
DWMLs see deep white matter lesions
dysthymic disorder
  childhood depression 145, 159
diagnosis 4, 9–10, 13
  old age depression 202, 204–5, 216–17, 220
  psychotherapies 98–9, 101
eating disorders 154
ECA see Epidemiological Catchment Area
economic studies 278–9, 296–9, 306
ECT see electroconvulsive therapy
effectiveness of care 280, 301–2
efficiency of care 280, 300
elderly see old age depression
electroconvulsive therapy (ECT)
  childhood depression 163, 164
diagnosis 7, 15–16, 18–19
  maintenance therapy 222–3
  old age depression 221–4, 226, 229–30, 234–5
EMEA see European Medicines Evaluation Agency
ENDOG scores 19
environmental depression 11, 13
ENRICH study 110–11
environmental transmission 149–50, 190
Epidemiological Catchment Area (ECA) 199
equity 280, 300
escitalopram 49–50, 56, 89, 98
ethnicity 78–9, 266
European Alliance Against Depression 305
European Medicines Evaluation Agency (EMEA) 161
evaluation of care 307

FA see fractional anisotropy
data factor analysis 7–8
family therapy 158–60
FDA see Food and Drug Administration fluoxetine
chaildhood depression 156–7, 161–2, 164, 166, 186–7
major depression 49–50, 54, 60, 93
old age depression 215
psychotherapies 109, 121
fluvoxamine 97–8
fMRI see functional magnetic resonance imaging
follow-up studies 227
Food and Drug Administration (FDA)
childhood depression 161
diagnosis 9
pharmacological treatment 49, 55, 57, 75, 86
fractional anisotropy (FA) 208
functional magnetic resonance imaging (fMRI) 116, 118
functionalised diagnosis 44–6
fuzzy set 23

General Health Questionnaire (GHQ) 281, 319–20, 325
genetic factors
childhood depression 149–50, 190, 194
pharmacological treatment 79
Geriatric Depression Scale 218
Geriatric Mental State (GMS) 258–9
GHQ see General Health Questionnaire
GMS see Geriatric Mental State
grief 2
guilt 11, 13

HADS see Hospital Anxiety and Depression Scale
Hamilton Rating Scale for Depression (HAM-D) 41, 106–8, 111, 121–2, 198, 212
heritability see genetic factors
hierarchical models 17
Hospital Anxiety and Depression Scale (HADS) 262, 281
HRSD see Hamilton Rating Scale for Depression
hypertensive crisis 60

ICD see International Classification of Diseases
ICER see incremental cost-effectiveness ratio
ICPC-2 see International Classification for Primary Care
imipramine 47, 54
inception cohorts 226
incremental cost-effectiveness ratio (ICER) 297
individual psychodynamic psychotherapy for depression (IPPD) 160
infantile depression 147–8
information technology 304–5
inpatient studies 230–1
Institute of Medicine 272
International Classification of Diseases (ICD) 1
alternative models 27–9
caseness 5, 31–3
childhood depression 146–7, 152
community 5–7
dimensional models 37–8
old age depression 198–9, 205, 228, 259
overview 4–5
primary care 277, 281, 320, 322
research and treatment difficulties 12–13
International Classification for Primary Care (ICPC-2) 322
internet-based CBT 112–13
interpersonal psychotherapy (IPT) 95, 99–104
acute phase efficacy 99–101
childhood depression 157–8
developing countries 140–1
evidence 133
pharmacological treatment 101–2
relapse/recurrence 102–3
response correlates 104
Interrupted Time Series (ITS) 290
interviews 153–4, 228, 324
IPPD see individual psychodynamic psychotherapy for depression
IPT see interpersonal psychotherapy
ischaemic stroke 204
Isle of Wight study 145
isocarboxazid 59, 61
ITS see Interrupted Time Series
guern P. R. 1, 14–15, 23
K-SADS interview 154
LADIS see Leucoaraisoisis and Disability
lamotrigine 166
Leucoaraiosis and Disability (LADIS) study 199–200
likelihood ratios 281
lithium carbonate 106
lofepramine 215
McHugh, P. R. 1, 14–15, 23
MADRS see Montgomery– Åsberg Depression Rating Scale
**INDEX 335**

magnetic resonance imaging (MRI) 116–17, 118, 212, 230

major depression
  childhood depression 159
diagnosis 3, 5–7, 9–12, 28–9, 40–1, 44–6
old age depression 200–8, 221, 229–30
pharmacological treatment 47–93
primary care 320, 328
psychotherapies 99–100, 102–3, 107
MAOIs see monoamine oxidase inhibitors
maprotiline 54
marital therapy (MT) 95, 119–20
Maudsley study 154, 155
MBCT see mindfulness-based cognitive therapy
melancholia 10–11, 13–22, 27–9, 32–3, 36, 40–3
*The Mental Health Atlas* 140
meperidine 60
metabolic variability 79
methylphenidate 213, 215
MFQ see moods and feelings questionnaire
mianserin 57–8
milnacipran 56–7, 90
mindfulness-based cognitive therapy (MBCT) 114–15, 138
Mini Mental State Examination (MMSE) 198, 223
minor depressive disorder
diagnosis 4
  old age depression 198, 205, 206–7, 216–17, 219
mirtazapine 50, 54, 57, 90
mixed subtyping model 1, 15–22
MMSE see Mini Mental State Examination
MMU see multiple medication use
moclobemide 49, 59, 61
monoamine oxidase inhibitors (MAOIs)
diagnosis 7, 12
dose variation 76
efficacy 84, 88, 90
historical development 86
major depressive disorder 47–9, 59–62
mechanism of action 59–61
psychotherapies 105
side-effects 60–1
Montgomery–Åsberg Depression Rating Scale (MADRS) 101–2, 223
mood disorders 36
moods and feelings questionnaire (MFQ) 149, 153
MRI see magnetic resonance imaging
MS see multiple sclerosis
MT see marital therapy
multiple medication use (MMU) 268–9
multiple sclerosis (MS) 111
multivariate statistical analysis 7–8, 16
music therapy 220
*N*-methyl-D-aspartate (NMDA) 87
National Centre for Clinical Infant Programs (Zero to Three) 147
National Comorbidity Survey (NCS) 132
National Institute for Health and Clinical Excellence (NICE)
  childhood depression 154, 161, 164
evidence 133–4
  primary care 285, 305–6, 323
National Institute of Mental Health (NIMH)
  old age depression 211, 216
  pharmacological treatment 86
  primary care 306
  psychotherapies 100
National Screening Committee 285–6
NCS see National Comorbidity Survey
NDRIs see norepinephrine dopamine reuptake inhibitors
nefazodone 50, 51, 101, 108–9
neurotic depression 13
NICE see National Institute for Health and Clinical Excellence
NIMH see National Institute of Mental Health
NMDA see *N*-methyl-D-aspartate
nonmelancholic depression 15–22, 27, 32–3
norepinephrine dopamine reuptake inhibitors (NDRIs) 50, 53, 58–9
  norepinephrine reuptake inhibitors (NRIs) 52–3, 54
  nortriptyline 54, 102, 214–17, 222
  not otherwise specified (NOS) categories 29, 192–3
  NRIs see norepinephrine reuptake inhibitors
OAD see overanxious disorder
OADIG see Old Age Depression Interest Group
obsessive compulsive disorder (OCD) 154
oestrogen replacement therapy 213
old age depression 197–269
  aetiology 208–9
  Asian experience 200, 258
  biological studies 208–9
  bipolar disorder 260
caregivers 262–3
cognitive impairment 199–200
correlation with younger adults 198–9
correlates 206–8
criteria for study validity 226–8
diagnosis 198–1, 228, 231, 258–9, 265–6
efficacy/effectiveness of treatment 209–24
electroconvulsive therapy 221–4, 226, 230, 234–5
old age depression (continued)
epidemiology 202–5, 258
evidence 210–11, 225–6, 234–5
pharmacological treatment 210, 211–17, 224–5, 230, 268–70
physical health and disability 206–7, 214–15, 218–19, 220
prognosis 226–33
psychotherapies 210, 217–20, 230, 263
research developments 235
risk factors 209
social factors 207–8
structural abnormalities 199–200
study results 228–9
subtypes of depression 200–1
suicidality 234
treatment-resistant depression 224–6
see also dementia
Old Age Depression Interest Group (OADIG) 214, 229
oppositional defiant disorder 148
outcome criteria 227
outpatient studies 228–30
overanxious disorder (OAD) 154
overdiagnosis 5–7
Oxford Centre for Evidence-Based Medicine 263
Parkinson’s disease 204, 206, 215
paroxetine
major depression 49, 89
old age depression 214, 216–17
psychotherapies 98, 103, 107–8, 115
pathways to care 273–4
Patient Health Questionnaire (PHQ9) 281, 283–4, 320
patient’s voice 323–4
Pennsylvania–Vanderbilt study 107
PEP see psycho-educational prevention programme
permutation plots 296
personality structure 46
PET see positron emission tomography
pharmacological treatment
childhood depression 160–5, 168, 186–7, 194
classification 81–2
compliance 293–5
continuation and maintenance 76
costs 75–6
developing countries 84–5
diagnosis 7, 9–10, 12, 15–16, 18–19
dose variation 76
drug–drug interactions 269
dual monoaminergic mechanism 53–9
efficacy 75, 78–9, 82, 88–90
ethnicity 78–9
evidence/evaluation 61, 78–9, 86–7
French experience 92–3
 genetic variability 79–80
historical development 47–9
long-term treatment 93
major depressive disorder 47–93
metabolic variability 79
multiple medication use 268–9
old age depression 210, 211–17, 224–6, 234, 268–9
primary care 278–9, 293–5
research developments 61–2, 86–7
single monoaminergic mechanism 49–53
special aspects 76–7
treatment-resistant depression 224–6
triple monoaminergic mechanism 59–61
phenelzine 49, 59, 61, 105–6
PHQ9 see Patient Health Questionnaire
physical health 206–7, 214–15, 218–19, 220
PMD see psychomotor disturbance
policy goals 279–80, 299–302, 305–6
positron emission tomography (PET) 116–17
post-partum depressive disorders 99–100
post-stroke depression 204, 215–16, 269
post-test probability 284–5
post-traumatic stress disorder (PTSD) 32, 190, 193
pregnancy 99–100
Preventative Service Task Force (PSTF) 285, 287
primary care 271–329
aetiology 275–6
cor-morbidity 276–7, 308, 322, 326, 320
collaborative care 286, 288–9, 291–99, 301–2, 305–6, 308
consultation–liaison 288, 291, 301
definitions 271–2
depression rating scales 281–4
developing countries 303, 319–20
diagnosis 274–5, 277–8, 280–7, 322–4, 328–9
disorder classification 273
economic studies 278–9, 295–8, 306
epidemiology 273–78
evidence/evaluation 306–7
Mexican experience 325–6
models 287–302
old age depression 231
pathways to care 273–4
patient’s voice 323–4
pharmacological treatment 276, 293
policy goals 279–80, 299–302, 305–6
prioritisation 302–4
prognosis 277–8
INDEX

psychotherapies 276
quality outcomes 284–7, 289–99
replacement/referral 289, 299, 302
research developments 305–6, 308–9
resource availability 302–4
screening 319–21
staff training 288, 289–91, 301, 304, 329
study results 228
problem-solving therapy (PST) 95, 96–9
acute phase efficacy 96–7, 98–9
pharmacological treatment 97–8
relapse/recurrence 98
Program to Encourage Active, Rewarding Lives for Seniors 220
prospective design 228
protriptyline 54
pseudodementia 21, 200
PST see problem-solving therapy
PSTF see Preventative Service Task Force
psycho-educational prevention programme (PEP) 110
psychodynamic psychotherapy 160, 217–18
psychomotor disturbance (PMD) 16–17, 19–21, 27, 38
psychotherapies 95–144
acute phase efficacy 96–8, 105–11, 119–22
adults 95–144
behaviour therapy 95, 117–19
brief dynamic psychotherapy 95, 120–2
childhood depression 156–60, 162, 167–8, 186–7, 194
cultural considerations 140–1, 143–4
depressive disorders 96, 99–101
diagnosis 107, 140–1, 143–4
everyday practice 135–6
evidence 96, 122–3, 132–4
family therapy 158–60
interpersonal psychotherapy 95, 99–104, 133, 140
interpersonal therapy 157–8
low- and middle-income countries 137–8
marital therapy 95, 119–20
old age depression 210–11, 217–18, 225–6, 263
primary care 276
problem-solving therapy 95, 96–9
psychodynamic psychotherapy 160
psychodynamic therapy 217–18
relapse/recurrence 98, 102–3, 113–16
research developments 123, 140–1
response correlates 104
trials 160
see also cognitive behaviour therapy; electroconvulsive therapy
psychotic depression
diagnosis 12, 14–22, 27–9, 32–3, 41
old age depression 221, 224
PTSD see post-traumatic stress disorder
puberty see adolescent depression
quality adjusted life-years (QALY) 298, 307
questionnaires
childhood depression 149, 153
primary care 281, 283–5, 319–20
rational-emotive behaviour therapy (REBT) 109
RDC see research diagnostic criteria
reboxetine 52–3, 89–90
REBT see rational-emotive behaviour therapy
receiver operator characteristic (ROC) curves 283
remission 3
replacement/referral 289, 299, 302
research diagnostic criteria (RDC) 198
resilience 323
resistance to treatment 162–3
resistance training 220
reversible dementia 199
risperidone 89
ROC see receiver operator characteristic
St John’s Wort 10
SARIs see serotonin antagonist reuptake inhibitors
schizophrenia 32–3
selective serotonin reuptake inhibitors (SSRIs)
childhood depression 160–2, 165, 168, 186
diagnosis 12, 18–19, 38, 82
efficacy 76–7, 78–9, 84, 88–9
major depressive disorder 49–50, 54, 61–2
mechanism of action 49–50
old age depression 211–17, 225, 234
psychotherapies 104, 109–11, 141, 144
research developments 86–7
side-effects 50, 82
self-criticism 2
self-esteem 2, 17–18
self-therapy 136
senile see old age depression
Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study
old age depression 198
pharmacological treatment 75
psychotherapies 109–10
sequential models 20–2
serotonin antagonist reuptake inhibitors (SARIs) 89
serotonin and norepinephrine reuptake inhibitors (SNRIs) 53, 55–7, 62, 89–90
serotonin receptor antagonists 51–2, 57–8
INDEX

serotonin reuptake enhancers 52  
sertraline  
  - childhood depression 164  
  - major depression 49–50, 54, 56, 89  
  - old age depression 217  
  - psychotherapies 101, 115  
  - severe depression 40–3, 320  
  - sexual dysfunction 50–2, 55–7, 61  
  - subcortical ischaemic depression  
SNRIs see serotonin and norepinephrine reuptake inhibitors  
  - social factors 207–8, 275–6  
  - somatic symptoms 13, 36  
  - SSRIs see selective serotonin reuptake inhibitors  
  - staff training 288, 289–91, 301, 304, 329  
  - Standardised Psychiatric Interview 325  
STAR*D see Sequenced Treatment Alternatives to Relieve Depression  
  - statistical analysis 7–8, 16  
  - stigma 266, 305, 326  
  - stress 207  
  - stress–vulnerability model 276  
  - stroke 204, 206, 215, 269  
  - subcortical ischaemic depression (SID) 201  
  - substance abuse 155  
  - subtyping models 8–9, 14–22  
  - suicidality  
    - childhood depression 155, 161–2, 165, 180, 194  
    - major depression 78–9, 91  
    - old age depression 234  
  - Suicide Probability Scale 153  
  - sympathomimetics 60  
  - TADS see Treatment for Adolescents with Depression Study  
  - Taiwan Old Age Depression Study (TOADS) 266  
  - TCAs see tricyclic antidepressants  
  - TDCRP see Treatment of Depression Collaborative Research Program  
  - telephone administered CBT 111–12  
  - test performance 281–2  
  - tianeptine 52, 89  
  - TMS see transcranial magnetic stimulation  
  - TOADS see Taiwan Old Age Depression Study  
  - transcranial magnetic stimulation (TMS) 261  
  - tranylcypromine 59, 61  
  - trazodone 51, 89  
  - Treatment for Adolescents with Depression Study (TADS) 154, 156–7, 165, 186–7  
  - Treatment of Depression Collaborative Research Program (TDCRP) 100, 106–7  
  - treatment-resistant depression 224–6  
  - tricyclic antidepressants (TCAs)  
    - childhood depression 160–1  
    - diagnosis 7, 19, 38  
    - efficacy 84, 88–9  
    - historical development 86, 88  
    - major depressive disorder 47–9, 53–4, 61–2  
    - mechanism of action 53–4  
    - old age depression 212–17, 225  
    - psychotherapies 96–7, 105, 141  
    - side-effects 54, 84, 90  
  - USPSTF see Preventative Service Task Force  
  - vagus nerve stimulation (VNS) 261  
  - valproate 166  
  - vascular depression 201  
  - venlafaxine  
    - major depression 50, 55–6, 90, 93  
    - old age depression 213, 224  
    - psychotherapies 115, 121  
  - VNS see vagus nerve stimulation  
  - vulnerability 276  
  - weight gain 51, 53–8, 82, 90, 93  
  - white matter hyperintensity (WMH) 199–200  
  - WHO see World Health Organization  
  - WMH see white matter hyperintensity  
  - World Health Organization (WHO)  
    - childhood depression 147  
    - old age depression 210  
    - see also International Classification of Diseases  
  - World Health Survey 85  
  - World Psychiatric Association (WPA) 75–6  
  - yoga 263